Menkes Disease Workup

  • Author: Celia H Chang, MD; Chief Editor: Amy Kao, MD   more...
 
Updated: Feb 14, 2012
 

Laboratory Studies

Copper and ceruloplasmin levels

Copper and ceruloplasmin levels may be normal in the milder variants and in the neonatal period. The total body copper content can be normal in the infant until 2 weeks after birth or later. Ceruloplasmin levels are 6-12 mg/dL initially and only later are considered pathologically low. Normal term newborns also have lower serum copper (32 mcg +/- 21 mcg/dL) with even lower levels in preterm infants. The fetal hair also may be normal.

Diagnostic findings are as follows:

  • Serum copper level less than 70 mg/dL (reference 80-160)
  • Serum ceruloplasmin level less than 20 mg/dL (reference 20-60)

Plasma catecholamines

Decreased norepinephrine level may be noted. Elevated hydroxyphenylalanine (DOPA) and dihydroxyphenylglycol (DHPG) ratio due to decreased activity of dopamine beta-hydroxylase may be observed, with higher values reflecting more severe disease. Diagnostic findings are as follows:

  • Greater than 5 in serum (normal 1.7-3.3)
  • Greater than 1 in cerebrospinal fluid (normal 0.3-0.7

Kaler et al found that asymptomatic infants at risk for Menkes disease could be separated into affected and unaffected based on plasma neurochemical profiles. Although there was potential overlap for the absolute levels of dopamine, dihydroxyphenylacetic acid, norepinephrine, and DHPG, 2 ratios clearly separated affected from unaffected infants. The differences were more distinct for older infants but were present in infants younger than 1 month.[10]

Diagnostic ratios

The ratio of dihydroxyphenylacetic acid to DHPG is as follows:

  • 13 +/- 6.6 for affected infants
  • 1.5 +/- .4 for unaffected infants

Ratio of dopamine to norepinephrine is as follows:

  • .83 +/- .71 for affected infants
  • .04 +/- .03 for unaffected infants

Urine homovanillic acid/vanillylmandelic acid (HVA/VMA) ratios above 4 may be noted. In once study, only 0.18% of controls had an HVA/VMA ratio greater than 4.[11]

Other findings

Other findings may include the following:

  • Increased intestinal and kidney copper
  • Decreased hepatic copper
  • Hypoglycemia
  • Deoxypyridinoline (D-Pyr): D-Pyr is synthesized by lysyl oxidase, which is defective in Menkes disease. D-Pyr levels in urine may remain low despite treatment.
Next

Imaging Studies

CT and MRI

The following may be noted:

  • White matter dysmyelination
  • Other white matter lesions may be symmetrical and involve the corpus callosum.[12]
  • Tortuous blood vessels
  • Atrophy: This was reported by Geller et al in a 5-week-old who was flaccid, without pupillary responses or Moro reflex when born at term. Cranial ultrasound and CT prior to that had demonstrated prominent fluid spaces.[13]
  • Subdural hematomas and effusions (see following image)Magnetic resonance imaging of the brain of a patieMagnetic resonance imaging of the brain of a patient with Menkes disease. Subdural effusion is evident in the left frontal lesion. Brain atrophy is also evident.
  • Cerebrovascular accidents

Angiography and magnetic resonance angiography

This may reveal elongated and tortuous vessels, both intracranially and extracranially

Proton magnetic resonance spectroscopy

Proton magnetic resonance spectroscopy shows elevated lactate and reduced N -acetyl aspartate (NAA)– total creatine (tCr) ratio with a z score of -3.0. After 120 days of treatment, the lactate signal disappeared, and the NAA signal increased to a z score of -1.5. The choline/Cr ratio also markedly decreased during treatment. Although, neuronal metabolism appeared improved, the neurologic symptoms and imaging abnormalities on MRI did not change.

Previous
Next

Other Tests

Cultured fibroblasts and lymphoblasts

These exhibit impaired copper metabolism, increased copper accumulation, and decreased copper release. Heterozygotic carriers also have abnormalities of fibroblast copper metabolism. Increased placental copper may be noted.

EEG

Early stage findings include the following:

  • Ictal EEG - Runs of slow spike waves and slow waves in the posterior regions
  • Interictal EEG - Multifocal and polymorphic slow waves or mixed slow spike-waves and slow waves

Intermediate stage findings may include the following:

  • Interictal EEG - Modified hypsarrhythmia or diffuse irregular slow waves and spike-waves

Late stage findings may include the following:

  • Interictal EEG - Multifocal high amplitude activity mixed with irregular slow waves

Visual-evoked potential

Findings may be low amplitude or absent.

Electroretinogram

Reduced amplitude and scotopic responses (rod isolated) may be noted in more severely affected than photopic responses (cone isolated).

Previous
Next

Histologic Findings

Light microscopy of the hair shaft

  • Pili torti - 180° twisting
  • Trichoclasis - Transverse fracture
  • Trichoptilosis - Longitudinal splitting
  • Trichorrhexis nodosa - Small, beaded swelling with fractures at regular intervals
  • Monilethrix elliptica - Swelling with intervening tapered constrictions

Autopsy of brain

  • Diffuse atrophy
  • Focal degeneration of neurons
  • Prominent neuronal loss in the cerebellum affecting the Purkinje cells
  • Abnormal dendritic arborization (so called "weeping willow") and perisomatic processes
  • Focal axonal swelling ("torpedoes")
  • Increased number and size of mitochondria on electron microscopy with electron-dense inclusions
  • Marked reduction of internal granule cells
  • Eosinophilic spheroid bodies (probably proliferated smooth endoplasmic reticulum) in the molecular layer

Skin

  • Thin strand of amorphous elastin associated with numerous microfibrils

Cerebral and systemic arteries

  • Tortuous with irregular lumens
  • Frayed and split intimal linings
  • Disrupted elastin fibers on electron microscopy

Muscle

  • Accumulation of glycogen
  • Predominance of type 2 fibers
Previous
Proceed to Treatment & Management
 
 
Contributor Information and Disclosures
Author

Celia H Chang, MD  Associate Health Sciences Clinical Professor, Department of Neurology, University of California, Davis, School of Medicine

Celia H Chang, MD is a member of the following medical societies: American Academy of Neurology and Child Neurology Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Beth A Pletcher, MD  Associate Professor, Co-Director of The Neurofibromatosis Center of New Jersey, Department of Pediatrics, University of Medicine and Dentistry of New Jersey

Beth A Pletcher, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics, American Medical Association, and American Society of Human Genetics

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Kenneth J Mack, MD, PhD  Senior Associate Consultant, Department of Child and Adolescent Neurology, Mayo Clinic

Kenneth J Mack, MD, PhD is a member of the following medical societies: American Academy of Neurology, Child Neurology Society, Phi Beta Kappa, and Society for Neuroscience

Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD  Attending Neurologist, Children's National Medical Center

Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, and Child Neurology Society

Disclosure: Nothing to disclose.

References

  1. Tümer Z, Møller LB. Menkes disease. Eur J Hum Genet. May 2010;18(5):511-8. [Medline]. [Full Text].

  2. Hardman B, Michalczyk A, Greenough M, et al. Hormonal regulation of the Menkes and Wilson copper-transporting ATPases in human placental Jeg-3 cells. Biochem J. Mar 1 2007;402(2):241-50. [Medline].

  3. Niciu MJ, Ma XM, El Meskini R, et al. Developmental changes in the expression of ATP7A during a critical period in postnatal neurodevelopment. Neuroscience. 2006;139(3):947-64. [Medline].

  4. Schlief ML, West T, Craig AM, et al. Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proc Natl Acad Sci U S A. Oct 3 2006;103(40):14919-24. [Medline].

  5. Linnebank M, Lutz H, Jarre E, et al. Binding of copper is a mechanism of homocysteine toxicity leading to COX deficiency and apoptosis in primary neurons, PC12 and SHSY-5Y cells. Neurobiol Dis. Sep 2006;23(3):725-30. [Medline].

  6. Moller LB, Tumer Z, Lund C, et al. Similar splice-site mutations of the ATP7A gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome. Am J Hum Genet. Apr 2000;66(4):1211-20. [Medline].

  7. Tang J, Donsante A, Desai V, Patronas N, Kaler SG. Clinical outcomes in Menkes disease patients with a copper-responsive ATP7A mutation, G727R. Mol Genet Metab. Nov 2008;95(3):174-81. [Medline].

  8. Bahi-Buisson N, Kaminska A, Nabbout R, et al. Epilepsy in Menkes disease: analysis of clinical stages. Epilepsia. Feb 2006;47(2):380-6. [Medline].

  9. Prasad AN, Levin S, Rupar CA, Prasad C. Menkes disease and infantile epilepsy. Brain Dev. Nov 2011;33(10):866-76. [Medline].

  10. Kaler SG, Holmes CS, Goldstein DS, Tang J, Godwin SC, Donsante A, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med. Feb 7 2008;358(6):605-14. [Medline].

  11. Matsuo M, Tasaki R, Kodama H, Hamasaki Y. Screening for Menkes disease using the urine HVA/VMA ratio. J Inherit Metab Dis. 2005;28(1):89-93. [Medline].

  12. Lee ES, Ryoo JW, Choi DS, Cho JM, Kwon SH, Shin HS. Diffusion-weighted MR imaging of unusual white matter lesion in a patient with Menkes disease. Korean J Radiol. Jan-Feb 2007;8(1):82-5. [Medline].

  13. Geller TJ, Pan Y, Martin DS. Early neuroradiologic evidence of degeneration in Menkes' disease. Pediatr Neurol. Oct 1997;17(3):255-8. [Medline].

  14. Sheela SR, Latha M, Liu P, et al. Copper-replacement treatment for symptomatic Menkes disease: ethical considerations. Clin Genet. Sep 2005;68(3):278-83. [Medline].

  15. Paulsen M, Lund C, Akram Z, Winther JR, Horn N, Møller LB. Evidence that translation reinitiation leads to a partially functional Menkes protein containing two copper-binding sites. Am J Hum Genet. Aug 2006;79(2):214-29. [Medline].

  16. Donsante A, Tang J, Godwin SC, Holmes CS, Goldstein DS, Bassuk A, et al. Differences in ATP7A gene expression underlie intrafamilial variability in Menkes disease/occipital horn syndrome. J Med Genet. Aug 2007;44(8):492-7. [Medline].

  17. Adaletli I, Omeroglu A, Kurugoglu S, Elicevik M, Cantasdemir M, Numan F. Lumbar and iliac artery aneurysms in Menkes' disease: endovascular cover stent treatment of the lumbar artery aneurysm. Pediatr Radiol. Oct 2005;35(10):1006-9. [Medline].

  18. Ambrosini L, Mercer JF. Defective copper-induced trafficking and localization of the Menkes protein in patients with mild and copper-treated classical Menkes disease. Hum Mol Genet. Aug 1999;8(8):1547-55. [Medline].

  19. Aoki T. Wilson's disease and Menkes disease. Pediatr Int. Aug 1999;41(4):403-4. [Medline].

  20. Barnes N, Tsivkovskii R, Tsivkovskaia N, Lutsenko S. The copper-transporting ATPases, Menkes and Wilson disease proteins, have distinct roles in adult and developing cerebellum. J Biol Chem. Mar 11 2005;280(10):9640-5. [Medline].

  21. Borm B, Moller LB, Hausser I, et al. Variable clinical expression of an identical mutation in the ATP7A gene for Menkes disease/occipital horn syndrome in three affected males in a single family. J Pediatr. Jul 2004;145(1):119-21. [Medline].

  22. Ferreira RC, Heckenlively JR, Menkes JH, Bateman JB. Menkes disease. New ocular and electroretinographic findings. Ophthalmology. Jun 1998;105(6):1076-8. [Medline].

  23. Gasch AT, Kaler SG, Kaiser-Kupfer M. Menkes disease. Ophthalmology. Mar 1999;106(3):442-3. [Medline].

  24. Gerard-Blanluet M, Birk-Moller L, Caubel I, et al. Early development of occipital horns in a classical Menkes patient. Am J Med Genet A. Oct 1 2004;130(2):211-3. [Medline].

  25. Godwin SC, Shawker T, Chang B, Kaler SG. Brachial artery aneurysms in Menkes disease. J Pediatr. Sep 2006;149(3):412-5. [Medline].

  26. Goodyer ID, Jones EE, Monaco AP, Francis MJ. Characterization of the Menkes protein copper-binding domains and their role in copper-induced protein relocalization. Hum Mol Genet. Aug 1999;8(8):1473-8. [Medline].

  27. Grange DK, Kaler SG, Albers GM, et al. Severe bilateral panlobular emphysema and pulmonary arterial hypoplasia: unusual manifestations of Menkes disease. Am J Med Genet A. Dec 1 2005;139(2):151-5. [Medline].

  28. Gu YH, Kodama H, Shiga K, et al. A survey of Japanese patients with Menkes disease from 1990 to 2003: incidence and early signs before typical symptomatic onset, pointing the way to earlier diagnosis. J Inherit Metab Dis. 2005;28(4):473-8. [Medline].

  29. Hsi G, Cox DW. A comparison of the mutation spectra of Menkes disease and Wilson disease. Hum Genet. Jan 2004;114(2):165-72. [Medline].

  30. Kaler SG. Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Pediatr Dev Pathol. Jan-Feb 1998;1(1):85-98. [Medline].

  31. Kim BE, Smith K, Petris MJ. A copper treatable Menkes disease mutation associated with defective trafficking of a functional Menkes copper ATPase. J Med Genet. Apr 2003;40(4):290-5. [Medline].

  32. Kim OH, Suh JH. Intracranial and extracranial MR angiography in Menkes disease. Pediatr Radiol. Oct 1997;27(10):782-4. [Medline].

  33. Kodama H, Gu YH, Mizunuma M. Drug targets in Menkes disease - prospective developments. Expert Opin Ther Targets. Oct 2001;5(5):625-635. [Medline].

  34. Kodama H, Murata Y. Molecular genetics and pathophysiology of Menkes disease. Pediatr Int. Aug 1999;41(4):430-5. [Medline].

  35. Kodama H, Murata Y, Kobayashi M. Clinical manifestations and treatment of Menkes disease and its variants. Pediatr Int. Aug 1999;41(4):423-9. [Medline].

  36. Kodama H, Sato E, Yanagawa Y, et al. Biochemical indicator for evaluation of connective tissue abnormalities in Menkes' disease. J Pediatr. Jun 2003;142(6):726-8. [Medline].

  37. Krajacic P, Qian Y, Hahn P, et al. Retinal localization and copper-dependent relocalization of the Wilson and Menkes disease proteins. Invest Ophthalmol Vis Sci. Jul 2006;47(7):3129-34. [Medline].

  38. Lane C, Petris MJ, Benmerah A, et al. Studies on endocytic mechanisms of the Menkes copper-translocating P-type ATPase (ATP7A; MNK). Endocytosis of the Menkes protein. Biometals. Feb 2004;17(1):87-98. [Medline].

  39. Mandelstam SA, Fisher R. Menkes disease: a rare cause of bilateral inguinal hernias. Australas Radiol. Apr 2005;49(2):192-5. [Medline].

  40. Menkes JH. Menkes disease and Wilson disease: two sides of the same copper coin. Part I: Menkes disease. Eur J Paediatr Neurol. 1999;3(4):147-58. [Medline].

  41. Mercer JF, Ambrosini L, Horton S, et al. Animal models of Menkes disease. Adv Exp Med Biol. 1999;448:97-108. [Medline].

  42. Munakata M, Sakamoto O, Kitamura T, et al. The effects of copper-histidine therapy on brain metabolism in a patient with Menkes disease: a proton magnetic resonance spectroscopic study. Brain Dev. Jun 2005;27(4):297-300. [Medline].

  43. Muz' NI, Matvienko AV. [Local injection of fraxiparine for the treatment of the lower extremity trophic ulcer]. Klin Khir. Nov-Dec 2002;51-2. [Medline].

  44. Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins University, Baltimore, MD. MIM Number: 309400. Accessed 1/10/00. Available at http://www.ncbi.nlm.nih.gov/omim/309400.

  45. Pedespan JM, Jouaville LS, Cances C, et al. Menkes disease: study of the mitochondrial respiratory chain in three cases. Eur J Paediatr Neurol. 1999;3(4):167-70. [Medline].

  46. Petris MJ, Mercer JF. The Menkes protein (ATP7A; MNK) cycles via the plasma membrane both in basal and elevated extracellular copper using a C-terminal di-leucine endocytic signal. Hum Mol Genet. Oct 1999;8(11):2107-15. [Medline].

  47. Petris MJ, Mercer JF, Camakaris J. The cell biology of the Menkes disease protein. Adv Exp Med Biol. 1999;448:53-66. [Medline].

  48. Poulsen L, Moller LB, Plunkett K, et al. X-linked Menkes disease: first documented report of germ-line mosaicism. Genet Test. 2004;8(3):286-91. [Medline].

  49. Sasaki G, Ishii T, Sato S, et al. Multiple polypoid masses in the gastrointestinal tract in patient with Menkes disease on copper-histidinate therapy. Eur J Pediatr. Dec 2004;163(12):745-6. [Medline].

  50. Suzuki M, Gitlin JD. Intracellular localization of the Menkes and Wilson's disease proteins and their role in intracellular copper transport. Pediatr Int. Aug 1999;41(4):436-42. [Medline].

  51. Tang J, Robertson S, Lem KE, et al. Functional copper transport explains neurologic sparing in occipital horn syndrome. Genet Med. Nov 2006;8(11):711-8. [Medline].

  52. Tumer Z, Birk Moller L, Horn N. Screening of 383 unrelated patients affected with Menkes disease and finding of 57 gross deletions in ATP7A. Hum Mutat. Dec 2003;22(6):457-64. [Medline].

  53. Tumer Z, Moller LB, Horn N. Mutation spectrum of ATP7A, the gene defective in Menkes disease. Adv Exp Med Biol. 1999;448:83-95. [Medline].

  54. Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. Neurobiol Dis. Aug 1999;6(4):221-30. [Medline].

  55. Zaffanello M, Fanos V. Rare urological abnormalities in 2 cases of Menkes' syndrome. J Urol. Oct 2003;170(4 Pt 1):1335. [Medline].

 
Previous
Next
 
Four-month-old patient with classic Menkes disease. His hair is depigmented and lusterless with pili torti and the skin is pale with eczema.
Diverticula of the bladder in a boy with Menkes disease.
The clavicles are short with hammer-shaped distal ends in a patient with Menkes disease.
Flared metaphyses of the ulna and radius in a 5-month-old patient with classic Menkes disease.
Lax skin in a patient with occipital horn syndrome.
Occipital horns (arrow) in a 14-year-old boy with occipital horn syndrome.
Magnetic resonance imaging of the brain of a patient with Menkes disease. Subdural effusion is evident in the left frontal lesion. Brain atrophy is also evident.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.